News Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.33 ^USD	+1.53%		-1.48%	-54.61%

May. 16	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte	CI
May. 09	Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference	May. 30	PR
Carisma Therapeutics : Corporate Presentation May 2024	May. 16	PU
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte	May. 16	CI
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 10	AQ
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Carisma Therapeutics : Corporate Presentation May 2024	May. 09	PU
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference	May. 06	PR
Carisma Therapeutics : Corporate Presentation May 2024	May. 02	PU
Carisma Therapeutics : Corporate Presentation May 2024	May. 02	PU
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	May. 02	PR
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	May. 02	CI
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting	Apr. 23	AQ
BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target	Apr. 11	MT
Carisma Therapeutics to Present at Upcoming Conferences	Apr. 03	PR
HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating	Apr. 02	MT
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Apr. 02	AQ
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline	Apr. 01	MT
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Carisma Therapeutics Announces Changes to its Board of Directors	Apr. 01	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Summary

Filters